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Abstract
In the hippocampus, as in many other CNS areas, nitric oxide (NO) participates in synaptic plasticity, manifested as changes
in pre- and/or postsynaptic function. While it is known that these changes are brought about by cGMP following activation
of guanylyl cyclase-coupled NO receptors attempts to locate cGMP by immunocytochemistry in hippocampal slices in
response to NO have failed to detect the cGMP elevation where expected, i.e. in the pyramidal neurones. Instead, astrocytes,
unidentified varicose fibres and GABA-ergic nerve terminals are reported to be the prominent NO targets, raising the
possibility that NO acts indirectly via other cells. We have re-investigated the distribution of cGMP generated in response to
endogenous and exogenous NO in hippocampal slices using immunohistochemistry and new conditions designed to
optimise cGMP accumulation and, hence, its detectability. The conditions included use of tissue from the developing rat
hippocampus, a potent inhibitor of phosphodiesterase-2, and an allosteric enhancer of the NO-receptive guanylyl cyclase.
Under these conditions, cGMP was formed in response to endogenous NO and was found in a population of pyramidal cell
somata in area CA3 and subiculum as well as in structures described previously. The additional presence of exogenous NO
resulted in hippocampal cGMP reaching the highest level recorded for brain tissue (1700 pmol/mg protein) and in cGMP
immunolabelling throughout the pyramidal cell layer. Populations of axons and interneurones were also stained. According
with these results, immunohistochemistry for the common NO receptor b1-subunit indicated widespread expression. A
similar staining pattern for the a1-subunit with an antibody used previously in the hippocampus and elsewhere, however,
proved to be artefactual. The results indicate that the targets of NO in the hippocampus are more varied and extensive than
previous evidence had suggested and, in particular, that the pyramidal neurones participating in NO-dependent synaptic
plasticity are direct NO targets.
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Introduction
Nitric oxide (NO) is a freely-diffusible transmitter that is critical
for the normal functioning of the nervous [1], cardiovascular [2]
and immune systems [3], amongst others. In the absence of
immune challenge, NO signals are generated by two NO synthase
(NOS) isoforms, namely the neuronal and endothelial subtypes,
abbreviated as nNOS and eNOS respectively [4]. Physiological
NO signal transduction occurs via GMP, which is synthesised on
activation of NO-targeted guanylyl cyclase enzymes. These
proteins are the only established NO receptors and they exist in
two isoforms, comprising an a1 or a2 subunit together with a
common b1 subunit [5]. Hydrolysis through one or more
phosphodiesterase (PDE) enzymes assists in the shaping of the
resultant cellular cGMP signals [6].
In brain, NO generation from nNOS is coupled to activation of
N-methyl-D-aspartate (NMDA) receptors and one of its roles is in
modifying the efficacy of synaptic transmission [1,7], such as in
long-term potentiation (LTP), a persistent enhancement of
synaptic strength frequently initiated by NMDA receptor channel
opening, and a putative correlate of learning and memory [8].
Based on studies done primarily at hippocampal CA3/CA1
synapses, NO-dependent LTP requires phasic, activity-dependent
NO formation from nNOS superimposed on a tonic low level of
NO generated by eNOS, with NO in both cases acting through
cGMP [9]. Interestingly, knockout studies indicate that both NO-
activated guanylyl cyclase isoforms are also needed for the LTP
[10].
At the cellular level, the simplest hypothesis is that NO-cGMP
signalling in LTP takes place directly at the excitatory synapses
between the participant pyramidal neurones, as has been
suggested by evidence derived largely from dissociated hippocam-
pal cultures [11–16]. When cGMP is located immunohistochem-
ically in the intact hippocampus following exposure to exogenous
NO, however, the nucleotide has been detected in astrocytes,
GABAergic nerve terminals, unidentified varicose fibres, and in
blood vessels, but not in pyramidal cells [17–26]. If correct, this
distribution would suggest a more complicated scenario in which
NO primarily targets cells that are not the direct participants in
LTP.
In an attempt to resolve the apparent mismatch between the
functional and anatomical evidence, the present work re-examines
the location of NO-stimulated cGMP accumulation in hippocam-
pal slices using previously untested experimental conditions
designed to maximise the cGMP response and thereby reveal
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targets of NO that may have been below the detection limit
beforehand.
Materials and Methods
Ethics statement
Experiments were conducted in strict accordance with the UK
Animals (Scientific Procedures) Act 1986, under a project licence
from the British Home Office and with approval of the University
College London ethical review panel.
Animals
Unless otherwise stated, male, 10-day-old Sprague Dawley rats
were used (Charles River, Kent, UK). Brain tissue from male, 8–
19 week-old, C57/Bl6/SV129 mice lacking the NO-targeted
guanylyl cyclase a1 subunit and their wild-type counterparts was
kindly provided by Dr. Adrian Hobbs (University College London,
London, UK). Male, 8-week-old, C57/Bl6 mice were obtained
from Charles River.
Pharmacological compounds
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-
1H-pyrazolo[3,4-b]pyridine (BAY 41-2272), 2-[(3,4-dimethoxy-
phenyl)methyl]-7-[(1R)-1-hydroxyethyl]-4- phenylbutyl]-5-methyl-
imidazo[5,1-f][1,2,4]triazin-4(1H)-one (BAY 60-7550) and 2-
(N,N-diethylamino)-diazenolate-2-oxide diethylammonium salt
(DEA/NO) were purchased from Axxora (Enzo Life Sciences,
Exeter, UK). 3-Isobutyl-1-methylxanthine (IBMX) and 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) were obtained
from Sigma-Aldrich Company, (Poole, Dorset, UK) and L-
nitroarginine (L-NNA) from Tocris Cookson (Avonmouth, Bristol,
UK). Stock solutions were made in DMSO (BAY 41-2772, BAY
60-7550, ODQ), 10 mM NaOH (DEA/NO), equimolar HCl (L-
NNA) or artificial cerebrospinal fluid (see composition below;
IBMX) and were at least 100-fold more concentrated than the
final concentration.
Antisera
The primary antibodies that were used are listed in Table S1.
Secondary antibodies for immunofluorohistochemistry were:
donkey anti-mouse Alexa 594 (used at 1:600), donkey anti-rabbit
Alexa 594 (1:1,500) and donkey anti-sheep Alexa 488 (1:1,000; all
from Invitrogen, Paisley, UK). A biotinylated donkey anti-rabbit
secondary antibody (1:200; Chemicon Europe, Hampshire, UK)
was used for immunoperoxidase staining. Western blotting for the
NO-targeted guanylyl cyclase a1 subunit or actin was done with a
goat anti-rabbit (diluted 1:15,000; Perbio Science, Northumber-
land, UK) or a donkey anti-goat (1:20,000; Santa Cruz
Biotechnology, Heidelberg, Germany) horseradish peroxidase-
conjugated secondary antibody, respectively.
Tissue preparation
Rats were killed by cervical dislocation and decapitation. The
hippocampi were swiftly dissected out into ice-cold artificial
cerebrospinal fluid comprising (in mM): 120 NaCl, 2 KCl, 1.19
MgSO4, 26 NaHCO3, 1.18 KH2PO4, 2 CaCl2 and 11 D-glucose,
equilibrated with 95% O2/5% CO2 to pH 7.4 (at 37uC). The
centre of the hippocampus was cut along the transverse plane at
400 mm intervals using a tissue chopper (McIlwain, Campden
Instruments, Loughborough, UK). Slices were then left to recover
in flasks of artificial cerebrospinal fluid held in a shaking water
bath (37uC) and continuously perfused with 95% O2/5% CO2.
After 1–2 hr, slices were randomly distributed to new flasks of
artificial cerebrospinal fluid, also held in a shaking water bath
(37uC) and perfused with 95% O2/5% CO2. NO-dependent
cGMP synthesis was stimulated by exposure to the allosteric
enhancer of NO-targeted guanylyl cyclase BAY 41-2272 (0.3–
30 mM, 5 min application) alone, or in combination with the NO
donor DEA/NO (10 mM, 2 min application). To increase the
cGMP signal-to-noise ratio, slices were pre-incubated for 15 min
with the general PDE inhibitor IBMX (1 mM) or an inhibitor of
PDE-2 (BAY 60-7550, 0.001–1 mM), the enzyme chiefly respon-
sible for cGMP hydrolysis in the hippocampus [26,27]. Other
inhibitors were pre-applied for 25 min.
Within 30 s of the end of stimulation, a proportion of slices were
submerged in 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4 at room temperature). These tissues were subsequently
used for fluorescent immunohistochemistry. At the same time the
remaining slices, which were used for cGMP measurement, were
individually inactivated by submersion in 250 ml boiling buffer
comprising 50 mM tris-HCl and 4 mM EDTA (pH 7.4 at room
temperature) for 15–20 min.
Immunofluorohistochemistry
Slices were fixed for 2 h in 4% paraformaldehyde, washed for
60 min in 0.1 M phosphate buffer (pH 7.4 at room temperature),
which was changed every 15 min, and cryoprotected using a series
of sucrose solutions ascending in concentration (5–20% in 0.1 M
phosphate buffer followed by 50% in optimal cutting temperature
medium (Raymond A Lamb, Eastbourne, UK); all stages done at
4uC). Slices were then embedded in neat cutting medium and
rapidly frozen on dry ice made extra cold with isopentane.
Transverse (10 mm-thick) sections were prepared on chrome
alum/gelatine-coated slides.
For immunolabelling, sections were rehydrated in tris-buffered
saline containing 0.1% triton-X (TBS-T; pH 7.4 at room
temperature; 2, 5 min washes) and then blocked in 10% donkey
serum (Millipore, Watford, UK). After 1 h, the primary antibod-
ies, diluted in 1% donkey serum, were applied at 4uC in a humid
environment. Control sections for the selectivity of the secondary
antibody received 1% serum but no primary antibody. Between
18–20 h later, sections were washed for 40 min in TBS-T (which
was changed every 10 min) and incubated with the secondary
antibodies for 1 h in the dark. Washes were then repeated and
sections mounted in Vectashield medium containing the nuclear
counterstain 49,69-diamidino-2-phenylindole (DAPI; both Vector
Laboratories, Peterborough, UK). Unless otherwise stated, solu-
tions were prepared in TBS-T and applied at room-temperature.
Z-stacks were captured using a Leica TCS SP confocal microscope
running Leica LCS SP2 software (Leica Microsystems, Heidel-
berg, Germany).
cGMP measurement
cGMP was measured by radioimmunoassay and normalised to
the total slice protein determined using the bicinchoninic acid
method (Perbio Science).
Immunoperoxidase staining
Rats were deeply anaesthetised using sodium pentobarbitone
(200 mg/ml/animal, injected intraperitoneally) and intracardially
perfused with ice-cold 0.1 M phosphate buffered saline, followed
by 1% cold paraformaldehyde (prepared in 0.1 M phosphate
buffer). The hippocampi were removed and fixed for a further 3 h
in 1% paraformaldehyde. Mice were killed by cervical dislocation
and decapitation. Mouse brains (minus cerebella, see western
blotting) were submerged in ice-cold paraformaldehyde (4%,
unless otherwise stated). The anterior and posterior ends of the
brain were trimmed, leaving the middle of the hippocampi intact,
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and the hemispheres were separated and fixed for a further 2 h at
4uC. All of the tissues were cryoprotected, sectioned and then
rehydrated as for immunofluorohistochemistry. Sections were
stained according to published methods [28], except that the
peroxidase suppressor (Perbio Science) was applied for 15 min
prior to blocking and that rat tissues were permeabilised with neat
acetone for 5 min immediately after rehydration. Counterstaining
was done with Mayer’s hemalum (Merck, Sharpe and Dohme,
Hertfordshire, UK). Control sections for the selectivity of the
secondary antibody did not receive the primary antibody.
Western blotting
The cerebella of the wild-type and NO-targeted guanylyl
cyclase a1-knockout mice that were used for immunoperoxidase
staining were removed and homogenised in an ice-cold tissue-lysis
buffer containing a protease inhibitor cocktail (Halt, Fisher
Scientific, Leicestershire, UK) and 1% sodium dodecyl sulphate.
The homogenate was heated (70uC for 10 min) and centrifuged at
13,000 rpm for 10 min (5uC). 50 mg of protein (measured using
the bicinchoninic acid method) in the resulting supernatant were
then separated by sodium dodecyl sulphate polyacrylamide gel
electrophoresis and transferred to a polyvinylidene fluoride
membrane. The gel running buffer comprised (in mM): 25 tris
base, 192 glycine and 3.5 sodium dodecyl sulphate. The gel to
membrane transfer buffer additionally contained 2.5% methanol.
Membranes were then rinsed in double distilled H2O and then
tris-buffered saline (TBS; pH 7.4 at room temperature), blocked
for 1 h in TBS containing 3% skimmed milk and washed for
5 min in TBS. The NO-targeted guanylyl cyclase a1 primary
antibody was then applied for 1 h, and the membranes were
washed (3, 5 min washes in TBS containing 0.05% tween-20, then
1, 5 min wash in TBS) and exposed to a horseradish peroxidase-
conjugated secondary antibody. Antibodies were diluted in 50%
blocking buffer. After 1 h, washes including TBS/tween-20 were
repeated and antibody binding was imaged on chemiluminescent
film using the SuperSignal West Pico Chemiluminescent Substrate
system (Thermo Fischer, Leicestershire, UK). To control for
effective protein loading, the membranes were then stripped of the
a1 antibody using Thermo Fischer Restore Western Blot Stripping
Buffer, washed (TBS, 5 min) and probed for actin by the above
methods, but incorporating extra washes to prevent background
staining and overexposure of the film.
Analysis
For histology, photographs are representative of data collected
from at least 3 animals (2 knock-out animals). Experimental and
control sections were prepared, stained and photographed in
parallel. The experimenter was blinded to the genotype of wild-
type and knock-out sections until after photographs were taken.
Control and experimental images were adjusted equally for
brightness and contrast using Adobe Photoshop (Adobe, Califor-
nia, USA).
cGMP measurements are mean values 6 standard error of the
mean and were collected using slices from at least 3 rats. Statistical
significance was determined by analysis of variance (ANOVA)
with Dunnett’s post hoc test using GraphPad InStat 3 software
(GraphPad Software Inc., California, USA) and was concluded
when p,0.05.
For immunoblot analysis, films were scanned and the average
grey value across each horizontal row of pixels in each vertical
protein lane was calculated using ImageJ (National Institutes of
Health Science, Maryland, USA). Lysates obtained from wild-type
and knock-out mice were processed on the same gels/membranes
and scanned images were adjusted equally for brightness and
contrast using Microsoft PowerPoint (USA). Data shown were
collected using cerebellar lysates and are representative of
forebrain lysates.
Results
Immunofluorescence for NO-evoked cGMP accumulation
Attempts to locate NO-evoked cGMP accumulation were
carried out using immature rat hippocampus. The young tissue
provides superior preservation during in vitro incubation [29] and
higher amplitude NO-dependent cGMP responses to NMDA [30]
compared with tissue from the adult.
Initial experiments aimed to reproduce conditions previously
used with adult hippocampal slices to determine if the targets of
NO might be age-dependent. The slices were pre-incubated with
the general PDE inhibitor IBMX (1 mM) and the allosteric
enhancer of NO-targeted guanylyl cyclase BAY 41-2272 (3 mM;
[31]). Slices were then fixed, sectioned and immunolabelled for
cGMP. In good agreement with the results of previous
histochemical studies on adult tissue [19–26], cGMP immunoflu-
orescence was detected in some blood vessels and a population of
scattered cells and fibres that were predominant in the stratum
radiatum and oriens of the CA1 subfield, most cells in the stratum
pyramidale being immunonegative (Figure 1A). Using double
immunofluorescent staining, many immunopositive cells were
found to express the astrocyte marker, glial fibrillary acidic protein
(GFAP; Figure 1B), consistent with previous reports on adult
rodent hippocampus [25,26]. GFAP-negative, cGMP-positive
cells, which may be interneurones or other types of glia, were
also observed. In accordance with PDE-2 being primarily
responsible for the breakdown of cGMP in the hippocampus
[26,27], a similar intensity and distribution of cGMP immunoflu-
orescence was observed using the PDE-2 inhibitor BAY 60-7550
(10 nM; [19]) in place of IBMX (Figure 1C–D).
To calibrate the conditions tested above, a concentration-cGMP
response curve for BAY 60-7550 (in the presence of 3 mM BAY
41-2722) was compiled. The results showed that the concentration
of BAY 60-7550 used in the above experiments (10 nM) was far
from optimal, the EC50 value being around 50 nM (Figure 2A). A
similar concentration-response curve for the allosteric enhancer
BAY 41-2722 in the presence of a near-maximal concentration of
BAY 60-7550 (1 mM), gave an EC50 of about 6 mM (Figure 2B).
With near-maximal concentrations of both compounds (10 mM
BAY 41-2272 and 1 mM BAY 60-7550) the amount of cGMP
generated was 4-fold higher than in slices pretreated with the
previously-used concentrations of both BAY compounds
(Figure 2A–C, compare white and blue bars).
When cGMP immunohistochemistry was repeated using the
improved conditions, there was a striking increase in the area and
intensity of cGMP staining (Figure 3A). In addition to pronounced
staining now appearing in the neuropil of all subfields, scattered
cells and blood vessels, a population of pyramidal neurones
(identified by their number, position and morphology) in the
subiculum and, more obviously, in area CA3/CA4 were
immunolabelled. Labelling throughout the dentate gyrus remained
comparatively weak. The cGMP staining was entirely prevented
by inhibition of NOS (L-NNA, 100 mM; (Figure 3B), showing that
the response was dependent on endogenously produced NO and
consistent with BAY 41-2722 acting as an allosteric enhancer to
potentiate the action of NO on its receptors [32]. The
immunostaining was also abolished by ODQ (10 mM), an NO
receptor antagonist (Figure 3C). L-NNA and ODQ similarly
blocked the cGMP response of whole hippocampal slices, as
measured by radioimmunoassay (Figure 2C, blue bars).
Targets of Nitric Oxide in the Hippocampus
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Given that the conditions so far examined are dependent on
basal NO production within the tissue, and that basal NO
concentrations are low relative to those seen on stimulation of
nNOS, for example with NMDA [33], the effect of adding
supplementary NO was tested. To do so, a concentration (10 mM)
of the NO donor DEA/NO that is maximal for cGMP
accumulation in adult rat hippocampal slices [9] was co-applied
with BAY 60-7550 (1 mM) and BAY 41-2272 (10 mM). Under
these conditions, cGMP levels measured using radioimmunoassay
were further increased by a factor of 3 (Figure 2C, red bars).
Consistent with this enhancement in overall slice cGMP,
immunohistochemistry showed that the intensity, as well as the
area, of cGMP immunofluorescent staining was augmented
(Figure 4A). Most obviously, the majority of pyramidal cells in
CA3 and a distinct proportion of those in CA1were now stained,
Figure 1. cGMP immunohistochemistry in immature rat
hippocampal slices. A,B. Sections from slices pre-treated with the
non-specific PDE inhibitor IBMX (1 mM) and the allosteric enhancer of
NO receptor-guanylyl cyclase BAY 41-2272 (3 mM) were immunolabelled
for cGMP (green) and counterstained using DAPI (blue nuclei). A.
Composite image of an entire hippocampal section. B. Double labelling
for the astrocyte marker GFAP (red, left) and cGMP (green, middle) in
the CA1 subfield. Colocalisation appears in yellow in the right-hand
image. Arrows without tails indicate double-labelled cells and arrows
with round tails, cGMP-positive, GFAP-negative cells. C, D. Slices were
pre-treated with the PDE-2 inhibitor BAY 60-7550 (10 nM) instead of
IBMX. Photographs are as in A and B. The number of GFAP-positive
fibres in D appears to be fewer than in B, because of the oblique plane
of section through the cell layer. Key: bv, blood vessel; DG, dentate
gyrus; gr, granule cell layer; h, hilus; lu, stratum lucidum; mol, stratum
moleculare; or, stratum oriens; pyr, stratum pyramidale; rad, stratum
radiatum; Sub, subiculum. Scale bar in A = 200 mm (also applies to panel
C); B = 30 mm; D= 50 mm.
doi:10.1371/journal.pone.0057292.g001
Figure 2. Quantification of cGMP accumulation. A. Concentra-
tion-cGMP response curve for BAY 60-7550 in the presence of BAY 41-
2272 in immature rat hippocampal slices. The EC50 value was 5069 nM
and the Hill Slope was 0.6560.04. B. Concentration-cGMP response
curve for BAY 41-2722 in the presence of BAY 60-7550. EC50 and Hill
slope values were 663 mM and 0.9660.12. In A and B, data shown in
red were collected from slices that were additionally pre-treated with
the NOS inhibitor L-NNA. Fits are logistic; adjusted R2 statistics of the fits
were.0.98. C. Effect of BAY compounds and the NO donor DEA/NO on
cGMP. Data shown in white, blue and red were collected in parallel with
the data shown in Figure 1C, 3A and 4A. Experimental conditions are
indicated by the colour-coded labels. In every experiment, basal cGMP
levels and the effect of L-NNA or the NO receptor antagonist ODQ on
the cGMP response were measured. Basal levels were pooled across
experiments. Asterisks: p,0.05 compared to basal by ANOVA with
Dunnett’s post hoc test. n=4–12.
doi:10.1371/journal.pone.0057292.g002
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as were numerous neurone-like cells in CA4 and the subiculum.
Some granule cells in the dentate gyrus also showed weak staining.
Again, the cGMP elevations detected both by radioimmunoassay
and by immunohistochemistry were prevented by ODQ (10 mM;
Figure 2C and 4B).
To provide a more detailed anatomical picture, experiments in
which slices were treated with DEA/NO (as above) were repeated
and sections from them subjected to dual labelling for cGMP and
some standard cellular markers. NeuN was used to identify
neurones, preferentially staining their nuclei. Pyramidal neurones
throughout the hippocampus were co-stained, the intensity and
frequency of staining being in the order CA3 and subiculum.-
CA4.CA1 (Figure 5). Many NeuN-positive cells lying outside the
pyramidal cell layer displayed very bright cGMP labelling,
indicating cGMP synthesis in interneurones. Nevertheless, some
cells staining for NeuN were immunonegative for cGMP, and vice
versa.
Fibres expressing the marker for axons, neurofilament-200
(NF200), were also found to accumulate cGMP. Co-localisation
was most obvious in CA1 (Figure 6A), CA3 (Figure 6B) and the
subiculum (Figure 6D) in the strata oriens, pyramidale and
radiatum. In CA4, cGMP-immunopositive axons were evident in
the hilus (Figure 6C). Throughout the tissue, cGMP-immunopo-
sitive, NF200-negative fibres were also visible, presumably
reflecting cGMP accumulation in astrocyte processes or dendrites,
as were NF200-positive, cGMP-negative structures.
As expected from previous findings (Figure 1B and D; [25,26]),
cGMP was also found associated with astrocytes, as indicated by
co-staining for GFAP (Figure 7A). Oligodendrocytes expressing
the myelin-associated marker 29,39-cyclic-nucleotide 39-PDE
(CNPase), by contrast, were cGMP immunonegative (Figure 7B).
Immunohistochemistry for NO-targeted guanylyl cyclase
subunits
In an attempt to determine if the results are compatible with the
distribution of NO receptor protein, immunoperoxidase staining
for the common b1 guanylyl cyclase subunit was carried out in the
same tissue (i.e. incubated immature rat hippocampal slices). As
indicated using an antibody from Cayman Chemical Company
(Table S1), the b1 subunit was present in all regions, including in
pyramidal and dentate granule cells, and in the neuropil generally
(Figure 8).
The common b1 subunit exists in combination with either an
a1 or a2 subunit to generate an active receptor-enzyme [5]. Both
of these a-subunits are required for LTP at hippocampal CA1
synapses but may perform different roles [10] and so knowledge of
Figure 3. cGMP immunofluorescence with near-maximal concentrations of both BAY compounds. Sections of slices pre-incubated with
BAY 60-7750 (1 mM) and BAY 41-2272 (10 mM) were immunolabelled for cGMP (green) and counterstained with DAPI (blue). A. Composite image of
an entire hippocampal section. Arrows mark pyramidal cell staining. B, C. cGMP immunolabelling was prevented by the NOS inhibitor L-NNA
(100 mM; B) or the NO receptor antagonist ODQ (10 mM; C). Photographs show area CA1. For key, see Figure 1 legend. Scale bar in A = 200 mm;
B = 50 mm (applies also to C).
doi:10.1371/journal.pone.0057292.g003
Figure 4. Effect of supplementary NO on cGMP immunofluo-
rescence. Slices were exposed to the NO donor DEA/NO (10 mM) in the
presence of 1 mM BAY 60-7550 and 10 mM BAY 41-2272. Sections were
immunolabelled for cGMP (green) and counterstained with DAPI (blue).
A. Composite image showing an entire hippocampal section. White
arrow: example of cGMP staining in a patch of granule cells. B.
Composite image of a whole section of a slice that was also pretreated
with ODQ (10 mM). For key, see Figure 1 legend. Scale bar in A= 200 mm
for both panels.
doi:10.1371/journal.pone.0057292.g004
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their location relative to the sites generating cGMP is desirable.
Unfortunately, an antibody for the a2-subunit is not available but
one for the a1-subunit (Table S1) has been widely used for
immunohistochemistry, including in the hippocampus [17,28,34–
38]. Having access to brain tissue from mice lacking the a1-
subunit afforded us the opportunity to test the specificity of this
antibody.
Encouragingly, in western blots of wild-type tissue, the a1-
antibody gave a single band of the correct molecular weight
(approximately 80 kDa) that was absent in the knockout tissue
(Figure 9A). When used in immunohistochemistry at a 1:400
dilution, the a1 antibody gave staining in pyramidal neurones,
blood vessels, neuropil and cells scattered throughout sections of
wild-type adult mouse hippocampus (Figure 9B). However, the
staining was identical in sections from a1-knockout mice
(Figure 9D). The lack of specific staining was unrelated to the
dilution of the antibody, as a 1:10,000 dilution, which was just
threshold for visible staining (primarily in a few scattered cells),
generated similar staining in the wild-type and knockout tissues
(Figure 9F–I). Further tests using the antibody with sections from
cerebellum and cerebral cortex showed similar non-specific
staining, with the exception of the cerebellar pia mater where
the staining was missing in the knockout animals (Figure S1). The
specificity seen in western blots, contrasting with non-specificity in
immunohistochemistry, is reminiscent of findings using an
antibody against an NMDA receptor subunit in the hippocampus
[39]. Moreover, the non-specific staining pattern reported in this
previous study (their Figure 3) is very similar to that seen here
(Figure 9B and D). An epitope unmasking technique (pretreating
the sections with pepsin) found to expose specific staining with the
NMDA receptor antibody was, however, unsuccessful when used
with the a1 antibody (Figure S2).
These findings raise questions over the specificity of the b1
antibody (Figure 8), which gave a similar pattern of staining to the
a1. b1-knockout mice were not available to us and are difficult to
obtain because of the high incidence of foetal and postnatal fatality
[40]. As an alternative, a second b1 antibody (Table S1; [25]) was
used. When tested in parallel in adult mouse hippocampus, the
two b1 antibodies gave comparable staining patterns (Figure S3).
An exception was the stratum lucidum in the CA3 subfield, which
was stained more heavily with one than the other.
Figure 5. Double labelling for cGMP and the neuronal marker,
NeuN. Experimental conditions were as in Figure 4A (1 mM BAY 60-
7550, 10 mM BAY 41-2272, 10 mM DEA/NO). Sections were labelled for
NeuN (red, left) and cGMP (green, middle) and counterstained with
DAPI (blue). Images show CA1 (A), CA3 (B), CA4 (C) and the subiculum
(D). Colocalisation appears yellow in the right-hand images. Arrows
without tails indicate double-labelled cells; arrows with round tails,
cGMP-positive, NeuN-negative cells; arrows with square tails, cGMP-
negative, NeuN-positive cells. See Figure 1 legend for the key. The scale
bar in A = 50 mm and applies to all panels.
doi:10.1371/journal.pone.0057292.g005
Figure 6. Double labelling for cGMP and the axonal marker,
NF200. Experimental conditions were as in Figure 4A and 5 (1 mM BAY
60-7550, 10 mM BAY 41-2272, 10 mM DEA/NO). Sections were labelled
for NF200 (red, left) and cGMP (green, middle) and were counterstained
with DAPI (blue). Images show CA1 (A), CA3 (B), CA4 (C) and the
subiculum (D). Colocalisation appears yellow in the right-hand images.
Arrows without tails indicate double-labelled fibres; arrows with round
tails, cGMP-positive, NF200-negative fibres; arrows with square tails,
cGMP-negative, NF200-positive fibres. See Figure 1 legend for the key.
The scale bar in A = 50 mm and applies to all panels.
doi:10.1371/journal.pone.0057292.g006
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Discussion
The principal findings of the present study are that, as judged by
cGMP immunohistochemistry, the targets of NO in the hippo-
campus are much more widespread than previous evidence of this
type had suggested and, in particular, that the principal neurones
participating directly in NO-dependent LTP are NO-responders,
rendering unnecessary more complicated hypotheses invoking the
participation of other cells. Further, results aimed at determining
the immunolocation of NO receptor protein raise doubts about the
veracity of current antibodies used for this purpose, although our
data obtained using cGMP immunohistochemistry are generally in
accordance with predictions based on the distribution of NO
receptor subunit mRNA, as studied by in situ hybridization.
No previous investigation of the location of cGMP by
immunohistochemistry in hippocampal slices has succeeded in
detecting the nucleotide in pyramidal neurones after exposure to
NO in combination with various PDE inhibitors [17–26]. We
could broadly replicate the results of these past studies (Figure 1)
but it transpired that the conditions used were substantially
submaximal for cGMP accumulation (Figure 2), suggesting that
the differences in pyramidal cell staining are simply explicable on
the basis of the size of the cGMP signal relative to the detection
threshold of the immunohistochemical method.
Previously, the highest level of cGMP accumulation reported in
hippocampal slices in response to NO in the presence of PDE
inhibitors (typically IBMX) was around 60 pmol/mg protein [19]
with values in the range 20–50 pmol/mg protein being common
in studies where cGMP immunohistochemistry was conducted in
parallel [24,26]. Assuming a protein concentration of 100 mg/ml
in brain (taking total protein to be 10% of weight and a tissue
density of 1 g/ml), 20–30 pmol/mg protein translates into an
overall cGMP concentration of 2–3 mM. Given that the cGMP
antibody used for immunofluorescence has a detection limit of
about 10 mM [41,42], it is unsurprising that the extent of visible
immunohistochemical labelling was limited. The predominance of
staining in astrocytes observed in previous studies [25,26] and in
Figure 1 may reflect a low PDE/high guanylyl cyclase activity of
these cells, reminiscent of astrocytes in the cerebellum where, even
in the absence of a PDE inhibitor, cGMP can reach near-
millimolar concentrations [43]. From measurements in the
hippocampal stratum radiatum [44], astrocytes take up only 4–
8% of the volume, so these cells having cGMP concentrations
above the threshold for detection would still be compatible with an
overall cGMP concentration of 2–3 mM.
In marked contrast to these previous findings, the cGMP level
we observed under optimal conditions was around 2 orders of
magnitude higher, at around 1700 pmol/mg protein (Figure 2).
This value appears to be the highest recorded for brain, surpassing
even maximal NO-evoked cGMP responses in the cerebellum,
which are around 1000 pmol/mg protein [45] and comparable to
the response amplitude observed in rat platelets, a pure population
of NO-responder cells, in the presence of a PDE inhibitor [46,47].
With an overall corresponding tissue cGMP concentration of
around 170 mM, it is predictable that the immunofluorescent
signal would be more intense and widespread (Figure 4).
Two methodological factors are likely to have favoured the
accumulation of higher levels of cGMP in the present study. First,
we used immature rat hippocampal slices, which have been shown
to generate around 5-fold more NO-dependent cGMP in response
to NMDA than those of the adult [30]. With few exceptions
[17,18], previous tests of the location of NO-evoked cGMP in the
hippocampus have been made using slices prepared from adult
rats [19–22,24,26] and/or mice [23,25]. The second factor is the
particular combination of compounds used to promote cGMP
accumulation: BAY 60-7550 to inhibit PDE-2, the major cGMP-
degrading enzyme in hippocampus [26,27], BAY 41-2772 to
increase the maximal NO-evoked guanylyl cyclase activity [31,32],
and DEA/NO to deliver authentic NO. This combination had not
been tested previously.
Even without supplementary NO, hippocampal cGMP was
comparatively high (580 pmol/mg protein; Figure 2), reflecting
Figure 7. Double labelling for cGMP and glial cell markers.
Experimental conditions were as in Figure 4A, 5 and 6 (1 mM BAY 60-
7550, 10 mM BAY 41-2272, 10 mM DEA/NO). Sections were doubled-
labelled for cGMP (green) and a marker for astrocytes (GFAP; red in A)
or oligodendrocytes (CNPase; red in B). Photographs show an area of
the CA3 subfield and are representative of findings throughout the
hippocampus. Arrows without tails: double-labelled cells and fibres;
arrows with round tails, cGMP-positive, glial cell marker-negative cells;
arrows with square tails, cGMP-negative, glial cell marker-positive cells.
The key is as in Figure 1 legend. Scale bar in A = 50 mm and applies to
both panels.
doi:10.1371/journal.pone.0057292.g007
Figure 8. Immunoperoxidase staining using an antibody raised
against the NO receptor-guanylyl cyclase b1 subunit. A–E.
Incubated immature rat hippocampal slices were sectioned and stained
for the b1 subunit (brown) using a primary antibody from Cayman
Chemical Company (Cay Ab). Photographs show an area of CA1 (A), the
subiculum (sub; B), CA3 (C), CA4 (D) and the dentate gyrus (E). F.
Control with the primary antibody omitted showing area CA3
(representative of the entire hippocampus). Tissues were fixed in 1%
paraformaldehyde. See Figure 1 legend for key. Scale bar in F = 100 mm
and applies to A–F.
doi:10.1371/journal.pone.0057292.g008
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endogenous NO acting under the potentiating influence of BAY
41-2272. From experiments on purified NO-activated guanylyl
cyclase [32], 10 mM BAY 41-2272 shifts the NO concentration-
response curve to the left by a factor of at least 20, enabling
marked stimulation of guanylyl cyclase by the picomolar NO
concentrations purported to exist in unstimulated brain slices [9].
Much of this resting NO concentration appears to be derived from
eNOS, which is capable of generating NO tonically over periods
of hours as a result of phosphorylation of the enzyme by the kinase
Akt [9,48]. Immunohistochemically, the difference in cGMP
labelling in response to endogenous and exogenous NO was
mainly one of degree (i.e. staining more intense and/or
encompassing more of the pyramidal cell layer; compare
Figure 3 and 4), suggesting that exogenous NO exposes targets
that would be accessed by higher levels of endogenously-generated
NO, which potentially rise to the low nanomolar range on nNOS
stimulation [33]. It is unclear why pyramidal cell somata (and
granule cell somata in the dentate gyrus) were the most resistant to
the accumulation of cGMP into the detectable range. High PDE
activity and/or low NO-activated guanylyl cyclase activity and/or
the signalling pathway being concentrated at sites distant from the
cell bodies are possible reasons.
The widespread distribution of cGMP immunoreactivity in the
hippocampus in response to NO implies that most of the
constituent cellular elements are potential NO targets, including
pyramidal neurones, interneurones, astrocytes and at least some
dentate granule cells. Some cells, notably CNPase-positive
oligodendrocytes (Figure 7B) and some presumed interneurones
(Figure 5), remained cGMP-immunonegative but their failure to
accumulate cGMP to detectable levels does not necessarily exclude
them as targets of NO, although some interneurones genuinely
appear to lack NO receptor subunits [35]: for example, their
dominant PDE may not be PDE-2.
Other approaches to the identification of NO targets in the
hippocampus are in situ hybridization and immunocytochemistry
for the NO receptive guanylyl cyclase subunits. In the immature
rat hippocampus [49], like in the adult [50], mRNA for the NO
receptor is widespread. The common b1 subunit and the a2
subunit appear to be strongly expressed in the pyramidal cell layer
and in the granule cells of the dentate gyrus [49]. The results of
Pifarre et al. [51] also indicate expression of a2 subunit mRNA in
scattered cells, presumably interneurones and/or glial cells (their
Figure 4B) whereas others report that this subunit is restricted to
pyramidal neurones [35]. The a1-subunit mRNA shows a more
diffuse distribution, reportedly being exclusively expressed in
subpopulations of interneurones in one study [35] but also
detected in pyramidal cells in another [51]. Irrespective of these
discrepancies in detail, our results are consistent with the broad
expression of NO-activated guanylyl cyclase indicated by in situ
hybridization.
There have been several descriptions of the distribution of NO-
activated guanylyl cyclase subunits in the hippocampus using
immunohistochemistry. Our results with two different antibodies
against the common b1-subunit are in general agreement with
each other (Figure 8 and S3) and with previous findings using this
method [25,52,53]. The b1-protein distribution is also compatible
with the mRNA distribution (see above) and with our cGMP
immunofluorescence results (Figure 4), signifying that the protein
detected by immunohistochemistry is genuine. However, this
conclusion is weakened by the fact that a similar distribution
obtained using an antibody against the a1-subunit proved non-
specific (Figure 9B–E). This antibody has been the only one used
to map the location of a1-protein beforehand and has led to the
conclusion that the a1b1 isoform is only in interneurones [17,35].
Whilst consistent with the in situ hybridization result carried out by
the same group [35], and with our results with the same antibody
used at a similar dilution (1:10,000), the persistence of the staining
in a1-knockout tissue raises concerns about the authenticity of the
staining (Figure 9F–I). Nevertheless, populations of interneurones
Figure 9. Evaluation of an antibody raised against the NO
receptor-guanylyl cyclase a1 subunit. Experiments were done
using adult mice. A. Western blots of lysates of wild-type (WT, black)
and a1-knockout (KO, black) cerebellum were probed for the a1 protein
(left) or, after removing the a1 antibody, actin (right). Grey values (given
in arbitrary units; au) for each horizontal row of pixels in the wild-type
and knockout lanes are shown in black (WT) and red (KO). Molecular
weights (kDa, far left) apply to both panels. Lysates from wild-type and
knockout animals were processed in parallel on the same gels/
membranes. B–E. Hippocampal sections prepared from the wild-type
(WT; B) and a1-knockout (KO; D) mice used in A were stained (brown)
using an antibody for the a1 subunit diluted 1:400. Images are a
composite of two photographs. Controls (same orientation as
experimental sections) with the primary antibody omitted are in C
and E. F–I. Staining of sections of wild-type (F) and a1-knockout (H)
hippocampus (CA1 area) using a 1:10,000 dilution of the a1 antibody. G
and I are controls (primary antibody omitted). Knockout and wild-type
tissues were processed in parallel and, for clarity, tissues were not
counterstained. The experimenter was blinded to genotype until all the
photographs were taken. Key: p = stratum pyramidale. Scale bar in
B = 500 mm and applies to B–E; scale in F = 155 mm is for F–I.
doi:10.1371/journal.pone.0057292.g009
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did display particularly intense cGMP immunoreactivity in our
study (Figure 5).
In the hippocampus, NO signalling has been most studied in the
context of LTP in the CA1 subfield and current evidence suggests
that after its formation by nNOS postsynaptically, NO acts both
pre- and postsynaptically to bring about a coordinated and
persistent increase in synaptic efficacy. Postsynaptically, functional
evidence indicates that NO, through cGMP, triggers gene
expression [14] and the insertion of AMPA receptors into the
cell membrane [15]. By showing cGMP accumulation in at least
some CA1 pyramidal neurones (Figure 4), our results provide
anatomical support for a postsynaptic site of action. Higher
resolution methods will be needed to explore the subcellular
locations of cGMP but there was obvious staining of the apical
dendrites of CA3 neurones (Figure 5B, 6B and 7) and, to judge
from the lack of empty dendritic profiles extending into stratum
radiatum in the CA1 subfield (Figure 4, 5A, 6A), it is probable that
pyramidal cell dendrites are NO-responsive. Immunohistochem-
istry for the b1-subunit of NO-activated guanylyl cyclase also
produces staining in CA1 dendrites ([25]; Figure S3). Presynap-
tically, NO reportedly increases neurotransmitter release through
cGMP [11,12]. Consistent with this site of action, cGMP labelling
was seen in axons throughout the hippocampus (Figure 6) but,
again, higher resolution would be needed to determine if cGMP
accumulates in nerve terminals specifically. Also consistent with a
presynaptic effect of NO, examination of the location of the b1
NO receptor subunit by immunohistochemistry reports presynap-
tic staining in some synapses [52,54], as do studies showing NO-
evoked cGMP accumulation in some nerve terminals [19,25].
Hence, an anatomical picture that coheres with functional
evidence with respect to hippocampal NO-cGMP signalling and
synaptic plasticity is beginning to taking shape.
Supporting Information
Table S1 Primary antibodies used. a University of Maas-
tricht, The Netherlands; b for immunoperoxidase staining; c for
western blotting; d for adult mouse hippocampus; e for immature
rat hippocampus; f Technische Universitat Braunschweig, Ger-
many.
(DOC)
Figure S1 Immunoperoxidase staining using the a1
antibody in sections of cerebellum and cerebral cortex.
Sagittal cerebellar and transverse cerebral cortex sections were
prepared from wild-type (WT) and a1 knockout (KO) mice and
immunostained (brown) by the same methods used for mouse
hippocampal sections. The a1 antibody was diluted 1:400. A–D.
Photographs show sections of WT (A) and KO (C) cerebellum. B
and D are controls (primary antibody omitted). Arrows point to
the pia mater. For clarity, tissues were not counterstained. E–H.
WT (E) and KO (F–H) cerebral cortex. Insets: controls (no
primary antibody) showing approximately the same regions as in
the larger photographs. Tissues were counterstained with Mayer’s
hemalum (blue). Key: gr, stratum granulare; mol, stratum
moleculare; Purkinje, Purkinje cell layer; wm, white matter. Scale
bar in A= 200 mm and applies to A–D; scale in E= 100 mm and
applies to E–H.
(TIF)
Figure S2 Effect of pepsin pretreatment on the speci-
ficity of immunostaining using the a1 antibody. Trans-
verse hippocampal sections prepared from wild-type and a1
knockout mice were rehydrated using TBS (5 min) and then
treated with 2 mg/ml pepsin (prepared in 30 mM HCl) for
10 min at 37uC according to published methods for epitope
unmasking [38]. Tissues were then stained using the immunoper-
oxidase method. The a1 antibody was used at a dilution that was
just suprathreshold for visible staining (1:10,000). A–D. Area CA1
of wild-type (A) and knockout (C) tissue. The primary antibody
was omitted in B and D. Sections were not counterstained. Key:
pyr, stratum pyramidale; rad, stratum radiatum. For all panels, the
scale bar = 200 mm. In other experiments, the pepsin concentra-
tion was altered to 0.2 or 4 mg/ml. Under these conditions, the
distribution of staining varied from that shown but was similarly
non-specific.
(TIF)
Figure S3 Immunoperoxidase staining in adult mouse
hippocampus using different antibodies for the b1
guanylyl cyclase subunit. A. Staining for b1 (brown) using
the Cayman antibody in a section fixed with 1% paraformalde-
hyde. Image is a composite of two photographs. B. Control for A
(no primary antibody); arrows point to non-specific staining. C.
Composite image of b1 staining using an antibody provided by S.
Behrends. D. Control for C (no primary antibody). Tissues were
counterstained with Mayer’s hemalum (blue). Scale bar in
A=500 mm and applies to all panels.
(TIF)
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